Physician profile
Lydia Parker
NPI 1912937079
$36,380.39
in general payments reported to CMS, 2019-2025
29 companies · $967 in 2025
The $967 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,123 · 2020: $1,014 · 2021: $2,028 · 2022: $9,365 · 2023: $14K · 2024: $1,797 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $4,173 · Travel and Lodging: $413 · Grant: $90.00 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,140.00 |
| Food and Beverage | $4,173.29 |
| Travel and Lodging | $412.90 |
| Grant | $90.00 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16,247.43 | 2019-2022 | |
| Abbvie INC. | $14,007.31 | 2021-2025 | |
| Merz North America, INC. | $898.50 | 2019-2023 | |
| Revance Therapeutics, INC. | $827.61 | 2024-2025 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $697.64 | 2022-2025 | Sotyktu |
| Incyte Corporation | $537.61 | 2021-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $513.00 | 2020-2025 | Blu-U, Odomzo |
| Galderma Laboratories, L.P. | $506.28 | 2019-2022 | |
| Amgen INC. | $320.60 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $308.37 | 2020-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $297.04 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $254.08 | 2019-2022 | |
| Pfizer INC. | $203.47 | 2019-2025 | |
| Janssen Biotech, INC. | $167.47 | 2019-2025 | Tremfya, Stelara, Simponi |
| Convatec INC. | $87.15 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $57.28 | 2021-2022 | |
| Leo Pharma INC. | $56.73 | 2022-2025 | Adbry |
| Biofrontera INC. | $54.78 | 2019-2025 | Ameluz |
| Ucb, INC. | $42.91 | 2022-2023 | Bimzelx |
| Vyne Pharmaceuticals INC. | $40.47 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.00 | 2019-2021 | |
| Strata Skin Sciences, INC. | $39.94 | 2019-2025 | Xtrac |
| Dermira, INC. | $39.26 | 2019 | |
| Almirall LLC | $38.31 | 2021-2022 | |
| Journey Medical Corporation | $24.35 | 2025 | |
| Dusa Pharmaceuticals, INC. | $20.70 | 2019 | |
| Dermavant Sciences, INC. | $20.69 | 2023 | Vtama |
| Springworks Therapeutics, INC. | $15.76 | 2025 | Gomekli |
| Verrica Pharmaceuticals INC. | $15.65 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.